Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Mayra Orellana"'
Publikováno v:
Ciencia del Suelo, Vol 34, Iss 1, Pp 145-154
Se optimizó un protocolo para la amplificación, mediante la reacción en cadena de la polimerasa (PCR), del ADN de hongos y bacterias totales como punto base en el estudio molecular de las comunidades microbianas del suelo presentes en tres ecosist
Externí odkaz:
https://doaj.org/article/a770b6b3c9b448548cfa8252bee9e751
Spliceosome-Targeted Therapies Trigger an Antiviral Immune Response in Triple-Negative Breast Cancer
Autor:
Lacey E. Dobrolecki, Siddhartha Tyagi, Jitendra K. Meena, Fabio Stossi, Swarnima Singh, Matthew J. Ellis, Bing Zhang, William Wu, Ik Sun Kim, Tiffany Y.T. Hsu, George Miles, Calla M. Olson, Jeffrey M. Rosen, Srinivas Chamakuri, Kristen L. Karlin, Heyuan Li, Damian W. Young, Nicholas J. Neill, Sarah J. Kurley, Alexander B. Saltzman, Xiang Zhang, Gino M. Canlas, Elizabeth A. Bowling, Hsiang-Ching Chung, Silvia Buonamici, Ido Golding, Michael T. Lewis, Thomas F. Westbrook, Rocio Dominguez-Vidana, Mayra Orellana, Charles Y. Lin, Anna Malovannaya, Fade Gong, Lihua Yu, Lukas M. Simon, Jarey H. Wang, Julien Dubrulle
Publikováno v:
Cell
Summary Many oncogenic insults deregulate RNA splicing, often leading to hypersensitivity of tumors to spliceosome-targeted therapies (STTs). However, the mechanisms by which STTs selectively kill cancers remain largely unknown. Herein, we discover t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c222a4910fd10cd5f75c72eac15d3b3
https://europepmc.org/articles/PMC8635244/
https://europepmc.org/articles/PMC8635244/
Autor:
Earlene M. Schmitt, Fabio Stossi, Matthew J. Ellis, Ivana Petrovic, James G. Christensen, Chad A. Shaw, Chad J. Creighton, Sufeng Mao, Hsiang Ching Chung, Jin-Peng Sun, Siddhartha Tyagi, Doug W. Chan, Amritha Nair, Julien Dubrulle, C. Kent Osborne, Rocio Dominguez-Vidana, Sarah J. Kurley, Charles Y. Lin, Rachel Schiff, Xiao Yu, Carolina Gutierrez, Mothaffar F. Rimawi, Kenneth L. Scott, Panagiotis Katsonis, Alexander Renwick, Tingting Sun, Lacey E. Dobrolecki, David M. Henke, Michael T. Lewis, Thomas F. Westbrook, Jeffrey W. Tyner, David J. Shields, Susan G. Hilsenbeck, Bing Zhang, Hui Li, Mayra Orellana, Olivier Lichtarge
Publikováno v:
Nature Medicine. 24:505-511
Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer diagnosed in more than 200,000 women each year1 and is recalcitrant to targeted therapies(2,3). Although TNBCs harbor multiple hyperactive receptor tyrosine kinases (RTKs)
Autor:
Sonal Gahlawat, Thomas F. Westbrook, Siddhartha Tyagi, Ronald J. Bernardi, Kathleen A. Scorsone, Tingting Sun, Mayra Orellana, Amritha Nair
Publikováno v:
Cancer Research. 78:A43-A43
As there is a paucity of targetable oncogenic drivers in pediatric solid tumors, we hypothesized that deficiency of select protein tyrosine phosphatases may allow proliferative signals to proceed unchecked in these cancers and that understanding thes
Autor:
Kathleen A. Scorsone, Ronald J. Bernardi, Thomas F. Westbrook, Sonal Gahlawat, Siddhartha Tyagi, Mayra Orellana
Publikováno v:
Cancer Research. 78:4291-4291
Pharmacologic inhibition of oncogenic ALK can yield clinical responses in a variety of cancer types, including non-small cell lung cancer, anaplastic large-cell lymphoma, and neuroblastoma; however, de novo and acquired resistance remain major proble
Autor:
Thomas A. Cooper, Siddhartha Tyagi, Antrix Jain, Ido Golding, Thomas R. Webb, Xiang Zhang, Azin Sayad, Nicholas J. Neill, Lukas M. Simon, Mayra Orellana, Sarah J. Kurley, Tingting Sun, Tiffany Y.T. Hsu, Rocio Dominguez-Vidana, Samuel O. Skinner, Richard Marcotte, Benjamin G. Neel, Gloria V. Echeverria, Chandraiah Lagisetti, Kristen L. Karlin, Christopher S. Bland, Alexander Renwick, Thomas F. Westbrook, Joel R. Neilson, Kathleen A. Scorsone, Jessica D. Hartman, Ronald J. Bernardi, Sung Yun Jung, Chad A. Shaw
Publikováno v:
Nature. 525(7569)
MYC (also known as c-MYC) overexpression or hyperactivation is one of the most common drivers of human cancer. Despite intensive study, the MYC oncogene remains recalcitrant to therapeutic inhibition. MYC is a transcription factor, and many of its pr